证券代码：688133 证券简称：泰坦科技 公告编号：2025-050 上海泰坦科技股份有限公司 关于公司实际控制人续签一致行动人协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海泰坦科技股份有限公司（以下简称"公司"）于 2025 年 12 月 26 日收到 公司实际控制人谢应波先生、张庆先生、张华先生、许峰源先生、王靖宇先生、 张维燕女士关于续签《一致行动人协议》的通知。鉴于各方在 2024 年 12 月 27 日 签署的《一致行动人协议》（以下简称"原《一致行动人协议》"）即将到期， 为完善公司治理，保证公司经营的连续性和稳定性，实现对公司实质且有效的控 制，各方续签了《一致行动人协议》，具体情况如下： 一、本次续签《一致行动人协议》的背景情况 截至本公告披露日，谢应波先生担任公司董事长，持有公司 9.88%的股份； 张庆先生担任公司董事、总经理，持有公司 4.59%的股份；张华先生担任公司董 事、副总经理，持有公司 4.59%的股份；许峰源先生担任公司董事，持有公司 4.58%的股份；王靖宇先生担任公 ...

Core Viewpoint - Titan Technology announced the renewal of the "Consistent Action Agreement" among its controlling shareholders, ensuring stability in the company's control and governance structure [1] Group 1 - The controlling shareholders, including Xie Yingbo, Zhang Qing, Zhang Hua, Xu Fengyuan, Wang Jingyu, and Zhang Weiyan, collectively hold 29.57% of the company's shares as of the announcement date [1] - The original agreement was signed on December 27, 2024, with a validity of one year, and the renewed agreement will also be valid for one year [1] - The agreement stipulates that the parties will act in concert on major company matters, with the opinions of the first party taking precedence in case of disagreement [1]

Core Viewpoint - Titan Technology announced the acquisition of 100% equity in Apollo Scientific Ltd. from Central Glass Co., Ltd., marking a significant step in its overseas expansion strategy [3][4]. Group 1: Acquisition Details - The acquisition was approved during the 17th meeting of the fourth board of directors on July 23, 2025 [3]. - Titan Technology has completed all necessary foreign investment filings and approvals, including obtaining certificates from the Shanghai Municipal Commission of Commerce and the Shanghai Development and Reform Commission [3]. - The transaction has passed the national security review in the UK, and all conditions for the deal's completion have been met [3][4]. Group 2: Strategic Implications - Following the completion of the acquisition, Apollo Scientific Ltd. will become a wholly-owned subsidiary of Titan Technology and will be included in the company's consolidated financial statements [4]. - The integration of Apollo Scientific is expected to enhance Titan Technology's product offerings and create synergies, including the establishment of overseas production and operational entities [4]. - This acquisition accelerates Titan Technology's global expansion efforts and aims to integrate the entire supply chain on a global scale [4].

Core Viewpoint - Titan Technology has successfully completed the acquisition of ASL, marking a significant step in its overseas expansion strategy and enhancing its operational capabilities in the chemical industry [1][3]. Group 1: Acquisition Details - The acquisition of 100% equity in ASL has been finalized, with all necessary foreign investment filings and approvals obtained, including certificates from the Shanghai Municipal Commission of Commerce and the Shanghai Development and Reform Commission [1]. - The total acquisition cost was £5.7564 million (approximately RMB 55.85 million), which has been fully paid to the seller, Central Glass Japan [1]. - ASL will be integrated into Titan Technology's consolidated financial statements as a wholly-owned subsidiary [1]. Group 2: ASL's Business Overview - ASL specializes in the distribution and customized services of chemical products, serving a diverse clientele that includes global pharmaceutical companies, biotechnology firms, academic research institutions, and chemical enterprises [2]. - The company offers over 100,000 types of compounds, including intermediates, fluorides, and life science reagents, ensuring a wide range of solutions for its customers [2]. - ASL has its own laboratories to maintain product quality and supply chain reliability, and it operates inventory locations in both the UK and the US [2]. Group 3: Strategic Implications - The acquisition aligns with Titan Technology's strategic development goals, promising enhancements in innovation, overseas production, and operational capabilities [3]. - Post-acquisition, the company plans to integrate ASL into its global supply chain, production technology, product development, and business teams, which is expected to strengthen profitability over time [2][3]. - ASL's business has faced cyclical downturns, with losses reported in 2023 and 2024, but a reduction in losses is anticipated for 2025 following the integration [2].

证券代码：688133 证券简称：泰坦科技 公告编号：2025-049 上海泰坦科技股份有限公司 关于收购境外公司股权的进展暨交割完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、交易情况概述 上海泰坦科技股份有限公司（以下简称"泰坦科技"或"公司"）于 2025 年 7 月 23 日召开第四届董事会第十七次会议，审议通过了《关于拟收购境外公司股 权并签署股权收购协议的议案》。公司拟使用自有或自筹资金收购中央硝子株式 会社（即 Central Glass Co., Ltd，东京证券交易所上市公司，股票代码 4044， 以下简称"Central Glass 日本"）持有的 Apollo Scientific Ltd.（英格兰注 册的私人股份有限公司，以下简称"标的公司"或"ASL"）100%的股权。（以下 简称"本次交易"） 二、交易进展情况 公司已完成本次交易相关的境外投资备案及审批程序，并先后取得上海市商 委出具的《企业境外投资证书》、上海市发展和改革委员会出具的《境外投资项 目备案通知书》，并通过了英国投 ...

Core Viewpoint - Titan Technology announced the approval of a proposal to acquire 100% equity of Apollo Scientific Ltd. from Central Glass, with the transaction completed on July 23, 2025 [1] Group 1: Acquisition Details - The acquisition will be financed through the company's own or raised funds [1] - The company has completed the necessary overseas investment filing and approval procedures, passing the UK's national security review [1] - A delivery confirmation agreement has been signed, and the full acquisition payment has been made [1] Group 2: Post-Acquisition Status - Following the completion of the transaction, Apollo Scientific will become a wholly-owned subsidiary of Titan Technology [1] Group 3: Risks Associated - The transaction carries risks such as foreign exchange losses and uncertainties regarding integration effectiveness [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 一、本次投资概述 上海泰坦科技股份有限公司（以下简称"公司"）于2025年9月25日披露《关于认购创业投资基金份额的 公告》（公告编号：2025-041），公司拟作为有限合伙人以自有资金2,900万元人民币认购上海泰礼璟 源创业投资合伙企业（有限合伙）（以下简称"接力基金第七期"或"合伙企业"）份额。 证券代码：688133 证券简称：泰坦科技 公告编号：2025-048 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海泰礼璟源创业投资合伙企业（有限合伙） 上海泰坦科技股份有限公司董事会 公司将密切关注合伙企业后续经营管理状况，敦促其加强投资管理及风险控制，切实降低投资风险，并 严格按照信息披露管理相关规定及时履行信息披露义务。敬请广大投资者注意投资风险。 特此公告。 根据《上海证券交易所科创板股票上市规则》《上海泰坦科技股份有限公司章程》及《对外投资管理制 度》等相关规定，本次对外投资已经公司总经理批准，无需提交公司董事会及股东大会审议。本次投资 不属于关联交易，亦不 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-048 接力基金第七期首关认缴出资为 24,200 万元，其中公司拟作为有限合伙人以 自有资金出资人民币 2,900 万元认购接力基金第七期 11.9835%的财产份额。待基 金完成最终募集后，基金总认缴出资额不超过 40,000 万元，其中泰坦科技认缴出 资额保持 2900 万元。合伙企业的出资额、合伙人名册及出资比例等信息以工商登 记为准。 上述投资具体内容详见公告。 二、进展情况介绍 上海泰坦科技股份有限公司 关于对外投资进展暨完成工商登记的公告 一、本次投资概述 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海泰坦科技股份有限公司（以下简称"公司"）于 2025 年 9 月 25 日披露 《关于认购创业投资基金份额的公告》（公告编号：2025-041），公司拟作为有 限合伙人以自有资金 2,900 万元人民币认购上海泰礼璟源创业投资合伙企业（有 限合伙）（以下简称"接力基金第七期"或"合伙企业"）份额。 根据《上海证券交易所科创板股票上市规则》《上 ...

泰坦科技公告，公司作为有限合伙人以自有资金2900万元人民币认购上海泰礼璟源创业投资合伙企业 （有限合伙）份额。接力基金第七期首关认缴出资为2.42亿元，泰坦科技认购11.9835%的财产份额。待 基金完成最终募集后，基金总认缴出资额不超过4亿元，泰坦科技认缴出资额保持2900万元。合伙企业 已完成工商注册登记，出资额为2.42亿元人民币，成立日期为2025年12月15日。 ...

Core Insights - Titan Technology is emerging as a key player in the domestic scientific services industry, breaking free from overseas technology monopolies and weak industrial foundations [1][6] - The company aims to enhance technological self-reliance and improve the overall efficiency of the innovation system during the 14th Five-Year Plan period [1][6] - Titan Technology has established a comprehensive manufacturing system covering three core categories: reagents, consumables, and instruments [2][5] Company Development - Titan Technology has evolved from a startup in 2007 to the first stock in the scientific services sector listed on the STAR Market in 2020 [1][6] - The company has built a full industrial chain manufacturing system and is expanding its production capacity with new bases in Shanghai, Hubei, and Anhui [2][5] - The Shanghai Songjiang base has achieved breakeven, while the Anhui base leads in ultra-pure solvent production in Asia [2][5] R&D and Innovation - In the first half of 2025, Titan Technology's R&D investment reached 80.36 million yuan, resulting in new products and 27 patents [2][5] - The company is focused on upgrading its manufacturing capabilities to meet high-end market demands, transitioning from "making bicycles" to "making airplanes" [2][5] Mergers and Acquisitions - Titan Technology has utilized mergers and acquisitions as a strategy to enhance its product capabilities, including the acquisition of Apollo Scientific Ltd. for approximately £5.75 million [5][6] - The company has successfully integrated acquired firms, leading to revenue growth in the first half of 2024 [5][6] Future Outlook - Titan Technology plans to enter a critical phase of results validation in the next 3 to 5 years, following significant investments in its production bases [3][7] - The company aims to compete globally by establishing a diversified brand matrix and leveraging its extensive customer base, which includes over 60,000 clients and more than 150 Fortune 500 companies [6][7]